Pelthos Therapeutics (PTHS)
Pelthos Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on NYSE.
142K
Short interest
settlement 2026-10-15
3.0
Days to cover
-1.1 days vs prior
54.4%
Short share of volume
2026-11-02
1,230
Fails to deliver
settlement 2026-10-14
Thu 12 Nov
Next earnings
estimated date
-$45K
Insider flow, 90 days
0 buys, 3 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 31 settlements in the table, 31 in the chart. JSONAs of 15 October 2026, short interest in PTHS is 142,250 shares, up 48,509 shares over the last month. Over the last 31 readings it ranged from 3,882 shares (15 September 2025) to 142,250 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 48K shares a day that is 3.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/pths" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 142,250 | +36.0% | 47,516 | 2.99 |
| 2026-09-30 | 104,573 | +11.6% | 25,686 | 4.07 |
| 2026-09-15 | 93,741 | -10.1% | 43,489 | 2.16 |
| 2026-08-31 | 104,324 | +8.1% | 50,577 | 2.06 |
| 2026-08-14 | 96,528 | +38.8% | 83,499 | 1.16 |
| 2026-07-31 | 69,531 | -1.6% | 109,574 | 1.00 |
| 2026-07-15 | 70,670 | +154.3% | 30,445 | 2.32 |
| 2026-06-30 | 27,790 | +32.0% | 28,124 | 1.00 |
| 2026-06-15 | 21,051 | -44.8% | 16,261 | 1.29 |
| 2026-05-29 | 38,114 | +22.9% | 23,627 | 1.61 |
| 2026-05-15 | 31,017 | -16.9% | 24,405 | 1.27 |
| 2026-04-30 | 37,302 | -18.8% | 18,938 | 1.97 |
| 2026-04-15 | 45,956 | -37.1% | 16,627 | 2.76 |
| 2026-03-31 | 73,037 | -11.5% | 4,223 | 17.30 |
| 2026-03-13 | 82,536 | +2.3% | 3,591 | 22.98 |
| 2026-02-27 | 80,653 | +0.6% | 7,592 | 10.62 |
| 2026-02-13 | 80,181 | +5.9% | 6,301 | 12.73 |
| 2026-01-30 | 75,690 | +20.7% | 9,286 | 8.15 |
| 2026-01-15 | 62,689 | +3.1% | 19,271 | 3.25 |
| 2025-12-31 | 60,830 | +15.3% | 23,661 | 2.57 |
| 2025-12-15 | 52,757 | +209.1% | 32,423 | 1.63 |
| 2025-11-28 | 17,067 | -1.6% | 24,524 | 1.00 |
| 2025-11-14 | 17,346 | -23.9% | 37,855 | 1.00 |
| 2025-10-31 | 22,810 | -8.4% | 11,739 | 1.94 |
| 2025-10-15 | 24,906 | -18.6% | 11,698 | 2.13 |
| 2025-09-30 | 30,599 | +688.2% | 17,296 | 1.77 |
| 2025-09-15 | 3,882 | -29.9% | 15,307 | 1.00 |
| 2025-08-29 | 5,534 | -28.4% | 4,049 | 1.37 |
| 2025-08-15 | 7,732 | +61.5% | 13,978 | 1.00 |
| 2025-07-31 | 4,789 | -68.2% | 17,180 | 1.00 |
| 2025-07-15 | 15,040 | -86.9% | 316,600 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of PTHS volume is 54.4%, down 39.4 points over the last five sessions. Over the last 30 readings it ranged from 32.1% (1 October 2026) to 96.9% (29 October 2026). The latest reading is 13.3 points below the 30-session average of 67.7%, on 88K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 48K | 88K | 54.4% | 587 |
| 2026-10-30 | 63K | 99K | 63.9% | 2,331 |
| 2026-10-29 | 4K | 4K | 96.9% | 0 |
| 2026-10-28 | 9K | 19K | 49.8% | 0 |
| 2026-10-27 | 19K | 35K | 53.6% | 2,085 |
| 2026-10-26 | 10K | 11K | 93.8% | 95 |
| 2026-10-23 | 6K | 8K | 76.4% | 2 |
| 2026-10-22 | 10K | 15K | 66.6% | 0 |
| 2026-10-21 | 12K | 16K | 76.5% | 0 |
| 2026-10-20 | 8K | 12K | 72.4% | 0 |
| 2026-10-19 | 10K | 21K | 49.0% | 0 |
| 2026-10-16 | 7K | 8K | 79.2% | 0 |
| 2026-10-15 | 4K | 5K | 76.7% | 0 |
| 2026-10-14 | 5K | 6K | 93.8% | 0 |
| 2026-10-13 | 17K | 19K | 88.2% | 0 |
| 2026-10-12 | 2K | 3K | 83.9% | 0 |
| 2026-10-09 | 802 | 1K | 71.0% | 0 |
| 2026-10-08 | 2K | 5K | 50.6% | 0 |
| 2026-10-07 | 1K | 2K | 74.4% | 0 |
| 2026-10-06 | 4K | 5K | 74.3% | 3 |
| 2026-10-05 | 2K | 4K | 58.0% | 0 |
| 2026-10-02 | 5K | 11K | 47.3% | 3 |
| 2026-10-01 | 2K | 6K | 32.1% | 3 |
| 2026-09-30 | 2K | 3K | 80.9% | 0 |
| 2026-09-29 | 4K | 4K | 83.4% | 0 |
| 2026-09-28 | 1K | 2K | 74.4% | 0 |
| 2026-09-25 | 2K | 4K | 54.3% | 0 |
| 2026-09-24 | 4K | 8K | 53.5% | 0 |
| 2026-09-23 | 8K | 16K | 51.2% | 0 |
| 2026-09-22 | 11K | 21K | 50.9% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in PTHS is 1,230 shares, up 1,085 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (15 July 2026) to 4,692 shares (7 August 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 1,230 | $20.29 | $25K |
| 2026-10-06 | 145 | $20.50 | $3K |
| 2026-10-05 | 208 | $20.60 | $4K |
| 2026-10-01 | 132 | $21.01 | $3K |
| 2026-09-30 | 418 | $20.92 | $9K |
| 2026-09-24 | 595 | $23.52 | $14K |
| 2026-09-23 | 201 | $23.24 | $5K |
| 2026-09-15 | 282 | $21.94 | $6K |
| 2026-09-03 | 10 | $25.03 | $250 |
| 2026-08-31 | 149 | $24.73 | $4K |
| 2026-08-14 | 597 | $28.95 | $17K |
| 2026-08-12 | 1,161 | $28.63 | $33K |
| 2026-08-11 | 14 | $29.00 | $406 |
| 2026-08-10 | 1,937 | $28.36 | $55K |
| 2026-08-07 | 4,692 | $29.45 | $138K |
| 2026-08-05 | 2,051 | $26.70 | $55K |
| 2026-08-04 | 1,625 | $26.84 | $44K |
| 2026-08-03 | 712 | $28.66 | $20K |
| 2026-07-30 | 1,262 | $25.74 | $32K |
| 2026-07-29 | 218 | $27.77 | $6K |
| 2026-07-28 | 314 | $27.59 | $9K |
| 2026-07-27 | 849 | $25.92 | $22K |
| 2026-07-23 | 107 | $26.47 | $3K |
| 2026-07-21 | 3,688 | $27.26 | $101K |
| 2026-07-20 | 400 | $26.99 | $11K |
| 2026-07-15 | 1 | $25.40 | $25 |
| 2026-07-02 | 607 | $28.00 | $17K |
| 2026-07-01 | 1,919 | $28.26 | $54K |
| 2026-06-29 | 979 | $29.03 | $28K |
| 2026-06-23 | 159 | $29.28 | $5K |
Insider trades
SEC Form 4, newest first. JSONInsiders at PTHS reported 3 open-market sells worth $45K in the last 90 days and no open-market buys. Latest filing: Pauls Matthew (Director) on 2026-10-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Pauls Matthew | Director | Sell | 786 | $21.00 | $17K | 14K |
| 2026-10-02 | Friedberg Ezra M | Director | Sell | 558 | $20.72 | $12K | 80K |
| 2026-10-02 | Greenleaf Peter | Director | Sell | 797 | $21.17 | $17K | 23K |
| 2026-07-02 | Pauls Matthew | Director | Sell | 94 | $27.36 | $3K | 14K |
| 2026-07-02 | Pauls Matthew | Director | Sell | 692 | $26.00 | $18K | 14K |
| 2026-07-02 | Greenleaf Peter | Director | Sell | 85 | $27.27 | $2K | 24K |
| 2026-07-02 | Greenleaf Peter | Director | Sell | 712 | $26.00 | $19K | 24K |
| 2026-07-02 | Friedberg Ezra M | Director | Sell | 24 | $27.33 | $656 | 81K |
| 2026-07-02 | Friedberg Ezra M | Director | Sell | 534 | $26.03 | $14K | 81K |
| 2026-06-15 | Friedberg Ezra M | Director | Sell | 59 | $27.94 | $2K | 82K |
| 2026-06-15 | Friedberg Ezra M | Director | Sell | 224 | $27.12 | $6K | 82K |
| 2026-06-11 | Davis Todd C | Director | Buy | 35K | $27.80 | $985K | 75K |
| 2026-06-11 | Davis Todd C | Director | Buy | 503 | $28.73 | $14K | 76K |
| 2026-05-22 | Francis Knuettel II | CFO, Treas & Secty | Sell | 2K | $26.84 | $40K | 11K |
| 2026-05-22 | Francis Knuettel II | CFO, Treas & Secty | Returned to company | 14K | $0.00 | $0 | 20K |
| 2026-05-14 | Friedberg Ezra M | Director | Tax withholding | 144 | $27.01 | $4K | 82K |
| 2026-04-02 | Pauls Matthew | Director | Sell | 371 | $21.36 | $8K | 15K |
| 2026-04-02 | Pauls Matthew | Director | Sell | 415 | $20.52 | $9K | 16K |
| 2026-04-02 | Malamut Richard | Director | Sell | 280 | $21.36 | $6K | 27K |
| 2026-04-02 | Malamut Richard | Director | Sell | 310 | $20.51 | $6K | 28K |
| 2026-04-02 | Greenleaf Peter | Director | Sell | 377 | $21.36 | $8K | 25K |
| 2026-04-02 | Greenleaf Peter | Director | Sell | 420 | $20.52 | $9K | 25K |
| 2026-04-02 | Friedberg Ezra M | Director | Sell | 265 | $21.36 | $6K | 82K |
| 2026-04-02 | Friedberg Ezra M | Director | Sell | 293 | $20.51 | $6K | 82K |
| 2025-12-23 | Einhorn Andrew J. | Director | Grant | 12K | price not stated in the filing | not stated | 12K |
| 2025-12-10 | Pauls Matthew | Director | Gift | 10K | $0.00 | $0 | 1K |
| 2025-11-25 | Friedberg Ezra M | Director | Sell | 2K | $28.00 | $56K | 30K |
| 2025-11-25 | Friedberg Ezra M | Director | Sell | 1 | $28.50 | $29 | 32K |
| 2025-11-25 | Friedberg Ezra M | Director | Sell | 2K | $28.14 | $56K | 32K |
| 2025-11-25 | Friedberg Ezra M | Director | Sell | 6K | $28.00 | $168K | 34K |
| 2025-11-13 | Malamut Richard | Director | Grant | 2K | $0.00 | $0 | 9K |
| 2025-10-02 | Pauls Matthew | Director | Exercise or conversion | 2K | $0.00 | $0 | 11K |
| 2025-07-02 | Francis Knuettel II | CFO, Treas & Secty | Grant | 33K | $0.00 | $0 | 33K |
| 2025-07-02 | Baxter Richard B | Director | Grant | 19K | $0.00 | $0 | 19K |
| 2025-07-02 | Rangarao Sai | Chief Commercial Officer | Grant | 31K | $0.00 | $0 | 31K |
| 2025-07-02 | Pauls Matthew | Director | Grant | 25K | $0.00 | $0 | 25K |
| 2025-07-02 | Greenleaf Peter | Director | Grant | 25K | $0.00 | $0 | 25K |
| 2025-07-02 | Plesha Scott M. | CEO and President | Grant | 84K | $0.00 | $0 | 84K |
| 2025-07-02 | Malamut Richard | Director | Grant | 19K | $0.00 | $0 | 28K |
| 2025-07-02 | Davis Todd C | Director | Grant | 19K | $0.00 | $0 | 40K |
| 2025-07-02 | Friedberg Ezra M | Director | Grant | 19K | $0.00 | $0 | 83K |
| 2025-07-02 | Pauls Matthew | Director | Exercise or conversion | 8K | $0.00 | $0 | 8K |
| 2025-07-01 | Friedberg Ezra M | Director | Conversion | 40K | $10.00 | $400K | 40K |
| 2025-07-01 | LIGAND PHARMACEUTICALS INC | 10% owner | Conversion | 1.5M | $10.00 | $15.0M | 1.5M |
| 2025-07-01 | Friedberg Ezra M | Director | Conversion | 40K | $10.00 | $400K | 40K |
| 2025-07-01 | Francis Knuettel II | Chief Financial Officer | Conversion | 10K | $10.00 | $100K | 10K |
| 2025-07-01 | Davis Todd C | Director, 10% owner | Conversion | 1.5M | $10.00 | $15.0M | 1.5M |
| 2024-11-13 | Davis Todd C | Director | Grant | 5K | $0.00 | $0 | 21K |
| 2024-11-13 | Friedberg Ezra M | Director | Grant | 2K | $0.00 | $0 | 63K |
| 2024-06-14 | Malamut Richard | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2024-06-14 | Davis Todd C | Director | Grant | 13K | $0.00 | $0 | 16K |
| 2024-06-14 | Friedberg Ezra M | Director | Grant | 6K | $0.00 | $0 | 61K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for PTHS worth $47K at the prices reported; 0 in the last 90 days worth $0. Latest: Francis Knuettel II filed on 2026-05-22 to sell 1,720 shares ($47K) from 2026-05-22.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-05-22 | Francis Knuettel IIOfficer | 2K | $47K | 0.049% | 2026-05-22 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON8 holders report 5% or more of PTHS in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Ligand Pharmaceuticals Incorporated at 49.9% of the class (5,189,177 shares), filed 2025-11-10 for an event on 2025-11-06.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-15 | 13G/Ano. 3 | Neil Shahrestaniindividual, parent holding company | 257K | 7.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | Ikarian Capital, LLCinvestment adviser | 257K | 7.7% | 2026-03-31 |
| 2026-05-07 | 13G/Ano. 2 | Maier Joshua Tarlowindividual | 337K | 9.9% | 2026-03-31 |
| 2026-05-07 | 13G/Ano. 2 | 3i Management LLCother entity | 337K | 9.9% | 2026-03-31 |
| 2026-05-07 | 13G/Ano. 2 | 3i, LPpartnership | 337K | 9.9% | 2026-03-31 |
| 2025-11-14 | 13G | Murchinson Ltd.investment adviser, corporation | 280K | 9.1% | 2025-09-30 |
| 2025-11-14 | 13G | Marc Bistricerparent holding company, individual | 280K | 9.1% | 2025-09-30 |
| 2025-11-10 | 13D/Ano. 1 | Ligand Pharmaceuticals Incorporatedcorporation | 5.2M | 49.9% | 2025-11-06 |
13F holders
Tracked managers holding PTHS at their latest 13F. JSON1 of the 30 tracked managers held PTHS at their latest 13F, $425K in total at quarter-end prices. Citadel Advisors is the largest at $425K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 15K | $425K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Pelthos Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Pelthos Therapeutics (PTHS), SEC CIK 1919246, listed on NYSE. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-05-22.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 1919246Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
- SYRESpyre Therapeutics
- SYYSysco
- TAT&T
- TAPMolson Coors
- TCOMTrip.com Group
- TDToronto-Dominion Bank
- TDGTransDigm Group
- TDYTeledyne Technologies
Datasets
Frequently Asked Questions
How much of PTHS is sold short?
What is PTHS's daily short volume?
Does PTHS have fails to deliver?
Are PTHS insiders buying or selling?
Have PTHS insiders filed to sell?
Who owns 5% or more of PTHS?
Which tracked 13F managers own PTHS?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.